Jackson Chris M, Blass Benjamin, Coburn Keith, Djandjighian Laurent, Fadayel Gina, Fluxe Andrew J, Hodson Steven J, Janusz John M, Murawsky Michael, Ridgeway James M, White Ronald E, Wu Shengde
Procter and Gamble Pharmaceuticals, The Mason Business Center, 8700 Mason-Montgomery Road, Mason, OH 45040, USA.
Bioorg Med Chem Lett. 2007 Jan 1;17(1):282-4. doi: 10.1016/j.bmcl.2006.07.007. Epub 2006 Nov 13.
Blockade of the Kv1.5 ion channel is a potentially atrial-selective avenue for the treatment of atrial fibrillation and atrial flutter. The development and biological evaluation of a series of thiazolidine-based blockers of Kv1.5 is described.
阻断Kv1.5离子通道是治疗心房颤动和心房扑动的一种潜在的心房选择性途径。本文描述了一系列基于噻唑烷的Kv1.5阻滞剂的研发及生物学评价。